Szemészet, 2018 (155. évfolyam, 1-4. szám)

2018-03-01 / 1. szám

npf

Centrális senosus chorionetinopathia

13. Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol 2010; 149: 361-363.

14. Desai UR, Alhalel AA, Campen TJ, Schiffman RM, Edwards PA, Jacobsen GR. Central serous chorioretinopathy in African Americans. J Natl Med Assoc 2003; 95: 553-559.

15. Salacz Gy. A retinopthia centralis serosa. Kandidátusi értekezés 1986. P 14.

16. Lehmann M, Bousquet E, Beydoun T, Behar-Cohen E PACHYCHOROID: an inherited condition? Retina (Phila Pa) 2015; 35: 10-16.

17. de Jong EK, Breukink MB, Schellevis RL, Bakker B, Mohr JK, et al. Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology 2015; 122(3): 562-570.

18. Eom Y, Oh J, Kim SW, Huh K. Systemic factors associated with central serous chorioretinopathy in Koreans. Korean J Ophthalmol 2012; 26: 260-264.

19. Tittl MK, Spaide RR Wong D, Pilotto E, Yannuzzi LA, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 1999; 128: 63-68.

20. Chen SN, Chen YC, Lián I. Increased risk of coronary heart disease in male patients with central serous chorioretinopathy: results of a population based cohort study. Br J Ophthalmol 2014; 98: 110-114.

21. Tewari HK, Gadia R, Kumar D, Venkatesh R Garg SR Sympatheticparasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest Ophthalmol Vis Sei 2006; 47: 3474-3478.

22. Haimovici R, Rumelt S, Melby J. 2003. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 2003; 110: 698-703.

23. Bouzas EA, Scott MH, Mastorakos G, Chrousos GR Kaiser-Kupfer Ml. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol 1993; 111: 1229-1233.

24. Bouzas EA, Karadimas R Pournaras CJ. 2002. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002; 47: 431-448.

25. Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc 1986; 84: 799-845.

26. Conrad R, Geiser E Kleiman A, Zur B, Karpawitz-Godt A. 2014. Temperament and character personality profile and illness-related stress in central serous chorioretinopathy. ScientificWorldJournal 2014; 63: 1687.

27. Roshani M, Davoodi NA, Seyyedmajidi MR, Zojaji H, Sherafat SJ, et al. Association of Helicobacter pylori with central serous chorioretinopathy in Iranian patients. Gastroenterol Hepatol Bed Bench 2014; 7: 63-67.

28. Michael JC, Pak J, Pulido J, de Venecia G. Central serous chorioretinopathy associated with administration of sympathomimetic agents. Am J Ophthalmol 2003; 136: 182-185.

29. Fraunfelder FW, Fraunfelder FT. Central serous chorioretinopathy associated with sildenafil. Retina 2008; 28: 606-609.

30. McCannel TA, Chmielowski B, Finn RS, Goldman J, Ribas A, et al. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol 2014; 132: 1005-1009.

31. Kovács B. Visual phenomena following light coagulation in central serous retinopathy. Documenta Opthalologica 1977; 44: 445-453.

32. Baran NV, Gürlii VR Esgin H. 2005. Long-term macular function in eyes with central serous chorioretinopathy. Clin Exp Ophthalmol

2005; 33: 369-372.

33. Kerényi Á, Seres A, Süveges I. Fluorescein és indocyaninzöld angioigráfia chorioretinopathia centrális serosaban. Szemészet 2000; 137: 39-45.

34. Nicholson B, Noble J, Forooghian R Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 2013; 58: 103-126.

35. Polak BC, Baarsma GS, Snyers B. Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment. Br J Ophthalmol 2005; 79: 922-925.

36. Sharma T, Shah N, Rao M, Gopal L, Shanmugam MP et al. Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology 2004; 111: 1708-1714.

37. Ficker L, Vafidis G, While A, Leaver R Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1988; 72: 829-834.

38. Roisman L, Magalhaes FP Lavinsky D, Moraes N, Hirai FE, et al. 2013. Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial. Ophthalmic Surg. Lasers Imaging Retina 2013; 44: 465-470.

39. Verma L, Sinha R, Venkatesh R Tewari HK. Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial 1ISRCTN84128484). BMC Ophthalmol 2004; 4: 15.

40. Golestaneh N, Picaud S, Mirshahi M. The mineralocorticoid receptor in rodent retina: ontogeny and molecular identity. Mol Vis 2002; 8: 221-225.

41. Gruszka A. Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: case report. European Review for Medical and Pharmacological Sciences 2013; 17: 1369-1373.

42. Zhao M, Valamanesh R Celerier I, Savoldelli M, Jonet L, et al. The neuroretina is a novel mineralocorticoid target: aldosterone upregulates ion and water channels in Müller glial cells. Faseb J 2010; 24: 3405-3415.

43. Danjuma, Mukherjee, Makaronidis, Osula. Converging Indications of Aldosterone Antagonists (Spironolactone and Eplerenone): A Narrative Review of Safety Profiles. Curr Hypertens Rep 2014; 16: 414.

44. Herold TR, Prause K, Wolf A, Mayer WJ, Ulbig MW. Spironolactone in the treatment of central serous chorioretinopathy - a case series. Graefes Arch Clin Exp Ophthalmol 2014; 252(12): 1985-91.

45. Ghadiali Q, Jung J J, Yu S, Patel SN, Yannuzzi LA. Central serous chorioretinopathy treated with mineralocorticoid antagonists: a oneyear pilot study. Retina 2016 Mar; 36(3): 611-618.

46. Kapoor KG, Wagner AL. Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis. Ophthalmic Res 2016; 56: 17-22.

47. Sun X, Shuai Y, Fang W, Li J, et al. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. Br J Ophthalmol 2017; 10: 125-127.

48. Gergely R, Kovács I, Nagy ZZs, Ecsedy M. Mineralokortikoid antagonista gyógyszer alkalmazása krónikus centrális szerozus chorioretinopathiában (cser) szenvedő betegek kezelésében. Szemészet 2017;

49. Gergely R, Kovács I, Schneider M, Resch, M, Papp A, Rácsán Zs, Nagy ZZs, Ecsedy M. Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: a comparative study of exudative and nonexudative fellow eyes. Retina 2017; 37(6): 1084-95.

Levelezési cím

Dn Ecsedy Mónika, 1085 Budapest Mánia u. 39., E-mail: ecsedy@yahoo.co.uk